Every year there are many prominent exclusivity losses in the pharmaceutical industry but this year’s list has some notable ones.
Number 1 on the list is Johnson & Johnson's Stelara, used to treat Psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. With $6.72 billion in US sales in 2024, the drug will be the largest US loss of exclusivity since AbbVie's Humira in early 2023.
Click here to see the list of Top 10.